15.75 -0.21 (-1.32%) | 02-07 19:43 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 18.89 | 1-year : | 22.07 |
Resists | First : | 16.18 | Second : | 18.89 |
Pivot price | 14.48 ![]() |
|||
Supports | First : | 13.18 | Second : | 11.34 |
MAs | MA(5) : | 15.38 ![]() |
MA(20) : | 13.86 ![]() |
MA(100) : | 11.48 ![]() |
MA(250) : | 12.3 ![]() |
|
MACD | MACD : | 0.9 ![]() |
Signal : | 0.8 ![]() |
%K %D | K(14,3) : | 94.4 ![]() |
D(3) : | 95.3 ![]() |
RSI | RSI(14): 75.6 ![]() |
|||
52-week | High : | 16.98 | Low : | 8.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LQDA ] has closed below upper band by 10.9%. Bollinger Bands are 77.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 16.03 - 16.11 | 16.11 - 16.17 |
Low: | 15.19 - 15.3 | 15.3 - 15.36 |
Close: | 15.6 - 15.76 | 15.76 - 15.86 |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Sat, 08 Feb 2025
Liquidia Corp's chief business officer sells $6,319 in stock - MSN
Fri, 07 Feb 2025
(LQDA) Investment Report - Stock Traders Daily
Thu, 06 Feb 2025
Liquidia Corp.: We Have Exposure To The Upside Now - Seeking Alpha
Fri, 31 Jan 2025
Liquidia Corporation's Long-Running Saga Is Coming To An End (NASDAQ:LQDA) - Seeking Alpha
Wed, 22 Jan 2025
Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last? - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 85 (M) |
Shares Float | 48 (M) |
Held by Insiders | 19.4 (%) |
Held by Institutions | 54.3 (%) |
Shares Short | 10,330 (K) |
Shares Short P.Month | 11,840 (K) |
EPS | -1.63 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.68 |
Profit Margin | 0 % |
Operating Margin | -743.3 % |
Return on Assets (ttm) | -40.7 % |
Return on Equity (ttm) | -181.8 % |
Qtrly Rev. Growth | -23.5 % |
Gross Profit (p.s.) | 0.12 |
Sales Per Share | 0.17 |
EBITDA (p.s.) | -1.14 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -75 (M) |
Levered Free Cash Flow | -70 (M) |
PE Ratio | -9.73 |
PEG Ratio | 0 |
Price to Book value | 22.82 |
Price to Sales | 89.83 |
Price to Cash Flow | -17.76 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |